The management and treatment options for secondary bone disease. Omi Parikh July 2013
|
|
- Victoria Doyle
- 5 years ago
- Views:
Transcription
1 The management and treatment options for secondary bone disease Omi Parikh July 2013
2 Learning Objectives: The assessment and diagnostic process of patients with suspected bone metastases e.g bone scan, MRI, ALP etc. Specific concerns such as pathological fracture, MSCC. Criteria for selection of patients for surgical treatments of bone metastases as prevention or treatment of skeletal related events The medical treatments of bone metastases as prevention or treatment of skeletal related events e.g. bisphosphonates, Denosumab, radiation, New emerging and treatments of bone metastases
3 Anatomy-Bone 1
4 Abnormal Bone Formation: Seed and Soil Analogy Seed: certain cancer cells have incredible affinity for growth in bones Soil: bone provides a fertile environment for cancer cell growth Hence, the vicious cycle of seed and soil
5 1) Assessment and diagnosis: Bone scan Alk phos Uncertainty: MRI CT Plain films Restage after hormones?bone turnover markers.
6 Diagnosis of Skeletal Complications of Malignancies Signs and symptoms Bone Pain Pathological Fractures Hypercalcaemia Spinal Cord Compression Blood tests Calcium levels (corrected Calcium levels) Bone resorption markers Radiology Plain-film radiography Radioisotope bone scan Computed tomography scan Magnetic resonance imaging
7
8
9
10 Timing: When does bone disease need managing? Hormone sensitive Hormone refractory Systemic control
11 Hormone sensitive: Palliative radiotherapy Calcium and vitamin d3 supplements? Zoledronic acid? denosumab
12 2: Complications: Specific concerns such as pathological fracture, MSCC.
13 Bone metastases may result in clinically significant and serious consequences of skeletal-related events (SREs) SREs are defined as 1,2 : Radiation to bone Pathological fracture Spinal cord compression Surgery to bone 1. Saad F, et al. J Natl Cancer Inst 2004;96:879 82; 2. Ibrahim A, et al. Clin Cancer Res 2003;9:
14 SREs have associated down-stream implications SRE Pathological fracture Radiation to bone Surgery to bone Spinal cord compression Potential complications Extended healing time Reduced survival 1,2 Loss of mobility Need for care/ nursing home residence (especially hip fracture) 3 Potential for pain flare after therapy 4 Myelosuppression 5 Repeat visits for treating spinal cord compression 6 Hospital stay In-hospital mortality rate ~8% 7 High rate of surgical complications 7,8 High failure rate; inability to restore function 7 Excruciating pain 8 Need for steroidal medications 8 Repeat visits for radiotherapy 6 Irreversible paraparesis or paraplegia 8 Loss of continence 8 1. Gainor, Buchert. Clin Orthopaed Rel Res 1983;178: ; 2. Saad F et al. Cancer 2007;110:1860 7; 3. Poor et al. Osteoporos Int 1995;5:419 26; 4. Loblaw et al. Supp Care Cancer 2007;15:451 5; 5. Hellman, Krasnow. J Palliat Med 1998;1:277 83; 6. Maranzano et al. Tumori 2003;89:469 75; 7. Katzer et al. Arch Orthopaed Trauma Surg 2002;122:251 8; 8. Loblaw et al. J Clin Oncol 2005;23:
15 Advanced solid tumours commonly metastasise to bone Cancer Incidence of bone metastases * Breast cancer 65 75% Prostate cancer 65 75% Lung cancer 30 40% *Based on post-mortem examinations. Coleman RE. Cancer Treat Rev 2001;27:
16 Bone metastasis/bone lesions lead to skeletal-related events (SRE) Breast cancer (24 months) Prostate cancer (24 months) Lung/other solid tumours (21 months) Pathological fractures 52% 25% 22% Hypercalcaemia of malignancy 13% 1% 4% Spinal cord compression 3% 8% 4% Radiation to bone* 43% 33% 34% Surgery to bone** 11% 4% 5% * Usually given for pain ** Usually a result of fracture Lipton A, et al. Clin Adv Hematol Oncol 2009;7(5 Suppl 11):1-30. Reprinted with permission from Clinical Advances in Hematology and Oncology.
17 Patients have increased chances of developing SREs as survival times improve Median time to first SRE vs median overall survival Breast 1, Prostate 3, Lung 5, Median time to first SRE Median overall survival Months 1. Lipton A, et al. Cancer 2000;88: ; 2. Miller K, et al. N Engl J Med 2007;357: ; 3. Saad F, et al. J Natl Cancer Inst 2002;94: ; 4. Kantoff PW, et al. N Engl J Med 2010;363;411 22; 5. Rosen LS, et al. Cancer 2004;100: ; 6. Sandler A, et al. N Engl J Med 2006;355:
18 % of patients with on-study SREs Prior SRE increases the risk for subsequent SREs 70 Breast cancer 1 Prostate cancer 2 Lung cancer and other solid tumors % 51% 52% 47% % 40% Prior SRE No Prior SRE 1. Kaminski M, et al. Poster presented at: ASCO Annual Meeting. June 5-8, 2004; New Orleans, LA. Abstract 857; 2. Saad F, et al. Clin Genitourin Cancer 2007;5:390 6; 3. Hirsh V, et al. Clin Lung Cancer 2004;6:170 4.
19 The impact of skeletal complications treatment costs burden carers Skeletal complications quality of life HSE resource survival rates
20 Probability SREs increase risk of death in men with prostate cancer Survival at day 360 No SRE: 49.7% 1 SRE: 28.2% P = 0.02, n = Survival (days) depuy V et al. Support Care Cancer 2007;15:
21 3: Surgical intervention: Criteria for selection of patients for surgical treatments of bone metastases as prevention or treatment of skeletal related events
22
23
24
25 Indications for surgical intervention: Pathological fracture? Impending Pain / mobility Cord compression
26 Pathological Fracture: The primary treatment of pathologic fracture is surgery where possible Radiotherapy has a major role in postoperative treatment treatment of fractures that are inoperable site such as a rib or pelvis, general poor condition of the patient.
27 Prostate Cancer X-rays show new blastic lesions from prostate cancer Bone metastases frequently involve spine Characteristic x-ray findings suggest enhanced osteoblastic activity Bone lesions more likely to cause pain; somewhat less likely to cause fracture compared to typical lytic lesion Studies of bone markers show patients with prostate cancer have as much evidence of bone resorption as patients with breast cancer
28 Prophylactic pinning: Impending vs non-pending fractures Non-impending fractures can be treated with primary radiotherapy Impending fractures:? > 30% risk of fracture within 6 months.
29 Mirels Scoring system:
30 Mirels conclusions: Score 7 or less prophylactic pinning not indicated Score 9 or more prophylactic pinning indicated Score 8: dilemma Rare for prostate cancer to be referred for prophylactic pinning.
31 Cord compression: MRI proven surgery followed by radiotherapy is better than radiotherapy alone Selected group of patients Isolated bone mets Fit for surgery Neurological symptoms Good prognosis (6 months)
32 Surgery vs Surgery +RT Sx+ RT RT Retained ability 126 days 35 days P=0.006 to walk Regained ability 56% 19% P=0.03 to walk Morphine/ day 0.4mg 4.8mg P=0.002 Dex / day 1.6mg 4.2mg P=0.009 OS 129 days 100 days P=0.08 Non sig
33 4) Medical management: Bisphosphonates, Denosumab, radiation
34 Current Therapeutic Approaches for Skeletal Complications of Malignancies Radiotherapy Endocrine therapy Chemotherapy Orthopaedic interventions Analgesia Bisphosphonates 1 Treatment of choice in hypercalcaemia of malignancy (HCM or TIH) Potent inhibitors of pathologic bone resorption Effective therapy for skeletal complications of bone metastases Denosumab 1. Body JJ, et al. J Clin Oncol
35 Zoledronic acid: Standard of care for symptomatic HRPC with bone mets STAMPEDE trial Usage varies
36 Denosumab: Novel mechanism of action Patient request it NICE approved for all solid malignancies apart from prostate cancer. bisphosphontes aren t indicated so neither should an alternative
37 Normal bone remodelling is tightly regulated RANK Ligand is an important mediator of bone resorption Osteoblasts release RANK Ligand RANK Ligand RANK Ligand binds to RANK on osteoclast precursor cells, which then develop into osteoclasts and become active Osteoblasts Osteoclast The resultant bone lost needs to be replaced by osteoblasts (formation) Active osteoclasts remove bone tissue (resorption) Adapted from Boyle WJ et al. Nature 2003;423: RANK, receptor activator of nuclear factor κ B
38
39
40 Denosumab targets RANK Ligand to break the vicious cycle Denosumab precisely binds to RANK Ligand, preventing activation of the RANK receptor on osteoclasts RANK Ligand By binding to RANK Ligand denosumab inhibits osteoclast formation, function and survival Denosumab Osteoblasts Tumour Osteoclast Denosumab prevents the maturation of osteoclasts, decreasing bone resorption and breaking the vicious cycle of bone destruction Adapted from Roodman GD. N Engl J Med 2004;350: ; Mundy GR. Nat Rev Cancer 2002;2:
41 Denosumab: Key Inclusion Criteria Castration-resistant prostate cancer and 1 bone metastases Key Exclusion Criteria Current or prior IV bisphosphonate treatment N = 950 denosumab 120 mg SC and placebo IV Q4W Supplemental calcium and vitamin D strongly recommended N = 951 zoledronic acid 4 mg IV* and placebo SC Q4W Primary Endpoint Secondary Endpoints Time to first on-study skeletal-related event (SRE) (noninferiority) Time to first on-study SRE (superiority) Time to first and subsequent on-study SRE(s) (superiority) *Per protocol and IV zoledronic acid label, product dose adjusted for baseline creatinine clearance and subsequent dose intervals determined by serum creatinine. No SC dose adjustments made due to increased serum creatinine. Fizazi K, et al. Lancet. 2011;377:
42 Baseline Characteristics IQR = interquartile range. ECOG = Eastern Cooperative Oncology Group. PSA = prostate-specific antigen. Fizazi K, et al. Lancet. 2011;377: Characteristic Denosumab (N = 950) Zoledronic Acid (N = 951) Median age, years (IQR) 71 (64 77) 71 (66 77) ECOG performance status of 0 or 1, n (%) 882 (93) 886 (93) Stratification Factors PSA at randomisation 10 g/l, n (%) 805 (85) 806 (85) Recent chemotherapy ( 6 weeks before randomisation), n (%) 132 (14) 132 (14) Previous SRE, n (%) 232 (24) 231 (24) Median time from diagnosis of bone metastasis to randomisation, months (IQR) 3.94 ( ) 5.19 ( )
43 Proportion of Subjects Without SRE Primary Endpoint: Time to First On-Study SRE 1.00 HR = 0.82 (95% CI, ) P (noninferiority) P = (superiority) Denosumab Zoledronic acid Kaplan-Meier Estimate of Median Months Patients at Risk: Study Month Zoledronic acid Denosumab Fizazi K, et al. Lancet. 2011;377:
44 5: New Treatments: Alpharadin
45
46 Alpharadin: Radiopharmaceutical Alpha radiation from radium-223 decay has an effect over a range of 2-10 cells less damage to surrounding healthy tissues half life of 11.4 days FDA approved May On CDF when licensed,? Given through nuclear medicine
47
48
49
50
51 Thank you Questions?
Elderly men with prostate cancer + ADT
Elderly men with prostate cancer + ADT Background and Rationale ADT and Osteoporosis Proportion of Patients With Fractures 1-5 Yrs After Cancer Diagnosis 21 18 +6.8%; P
More informationBone Metastases. Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital
Bone Metastases Sukanda Denjanta, M.Sc., BCOP Pharmacy Department, Chiangrai Prachanukroh Hospital 1 Outline Pathophysiology Signs & Symptoms Diagnosis Treatment Spinal Cord Compression 2 General Information
More informationDenosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma
Denosumab (AMG 162) for bone metastases from solid tumours and multiple myeloma September 2008 This technology summary is based on information available at the time of research and a limited literature
More informationCastrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Castrate-resistant prostate cancer: Bone-targeted agents Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for: Amgen, Astellas,
More informationIsotopes and Palliative Radiotherapy for bone metastases
Isotopes and Palliative Radiotherapy for bone metastases Rationale for Bone-seeking Isotope Therapies in Prostate Cancer > 90% of patients with advanced prostate cancer have bone metastases which can be
More informationManagement of Acute Oncological emergencies
Management of Acute Oncological emergencies Malignant Spinal cord compression (MSCC) Neutropenic sepsis Superior vena caval obstruction Hypercalcemia Hyponatremia Bowel obstruction Brain Metastasis with
More informationIsotopes and Palliative Radiotherapy for bone metastases
Isotopes and Palliative Radiotherapy for bone metastases Rationale for Bone-seeking Isotope Therapies in Prostate Cancer > 90% of patients with advanced prostate cancer have bone metastases which can be
More informationThe management and treatment options for secondary bone disease. Dr Jason Lester Clinical Oncologist Velindre Cancer Centre
The management and treatment options for secondary bone disease Dr Jason Lester Clinical Oncologist Velindre Cancer Centre Aims Overview of bone metastases management in castrate-refractory prostate cancer
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationBone Health in Patients with Multiple Myeloma
Bone Health in Patients with Multiple Myeloma Amrita Y. Krishnan, MD Director Judy and Bernard Briskin Myeloma Center City of Hope Comprehensive Cancer Center Bone Health Bisphosphonates in Space Bone
More informationBone Health in the Cancer Patient. Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018
Bone Health in the Cancer Patient Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018 Overview Healthy bone is in a constant state of remodelling
More informationBone targeting: bisphosphonates, RANK-ligands and radioisotopes. Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017
Bone targeting: bisphosphonates, RANK-ligands and radioisotopes Dr Lisa Pickering Consultant Medical Oncologist ESMO Preceptorship Singapore 2017 Disclosures Institutional Research Support/P.I. Employee
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Radium-223 chloride for the treatment of bone metastases in castrate resistant prostate cancer Draft scope Draft
More informationCurrent Management of Metastatic Bone Disease
Current Management of Metastatic Bone Disease Evaluation and Medical Management Dr. Sara Rask Head, Medical Oncology Simcoe Muskoka Regional Cancer Centre www.rvh.on.ca Objectives 1. Outline an initial
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationManaging Bone Pain in Metastatic Disease. Rachel Schacht PA-C Medical Oncology and Hematology Associates Presented on 11/2/2018
Managing Bone Pain in Metastatic Disease Rachel Schacht PA-C Medical Oncology and Hematology Associates Presented on 11/2/2018 None Disclosures Managing Bone Pain in Metastatic Disease This lecture will
More informationBone-targeted therapies for prostate cancer in Institut Gustave Roussy Villejuif, France
Bone-targeted therapies for prostate cancer in 2012 Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards or speaker for: Amgen, Astellas-Medivation,
More informationSpinal cord compression as a first presentation of cancer: A case report
J Pain Manage 2013;6(4):319-322 ISSN: 1939-5914 Nova Science Publishers, Inc. Spinal cord compression as a first presentation of cancer: A case report Nicholas Lao, BMSc(C), Michael Poon, MD(C), Marko
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationThe Latest is the Greatest. Future Directions in the Management of Patients with Bone Metastases from Breast Cancer
City Wide Medical Oncology Rounds Friday Sept. 21 st, 2007 The Latest is the Greatest Future Directions in the Management of Patients with Bone Metastases from Breast Cancer Mark Clemons Head, Breast Medical
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support
More informationHOW I DO IT. Introduction. BARKIN J. How I Do It: Managing bone health in patients with prostate cancer. Can J Urol 2014;21(4):
HOW I DO IT How I Do It: Managing bone health in patients with prostate cancer Jack Barkin, MD Department of Surgery, University of Toronto, Humber River Hospital, Toronto, Ontario, Canada BARKIN J. How
More informationManagement of castration resistant prostate cancer after first line hormonal therapy fails
Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 11 April 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 11 April 2012 XGEVA 120 mg, solution for injection 1 glass vial of 120 mg/1.7 ml (CIP code: 217 253-8) 4 glass vials
More informationACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS.
ACTUALIZACIONES EN TRATAMIENTOS DIRIGIDOS AL HUESO. COMBINACIÓN CON OTRAS ESTRATEGIAS TERAPÉUTICAS. ÁLVARO PINTO Servicio de Oncología Médica Hospital Universitario La Paz IdiPAZ, Madrid INTRODUCTION High
More informationManaging Skeletal Metastases
School of Breast Oncology 2012 Managing Skeletal Metastases Cathy Van Poznak, MD Assistant Professor University of Michigan Comprehensive Cancer Center Saturday, November 3, 2012 Learning Objectives: Define
More informationVol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab 120mg for Bone Metastases
ה מ ר א פ הביטאון לענייני תרופות ISRAEL DRUG BULLETIN 19 years of unbiased and independent drug information P H A R x M A Vol. 19, Bulletin No. 108 August-September 2012 Also in the Bulletin: Denosumab
More informationDevelopment and Complications of Bone Metastases in Men With Prostate Cancer
Development and Complications of Bone Metastases in Men With Prostate Cancer Explore the Causes Understand the Consequences Natural History of Prostate Cancer Progression Many prostate tumors may become
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Zoledronic acid Therapeutic Area of Trial Breast cancer, prostrate cancer Approved Indication Prevention of skeletal related events
More informationProstate cancer update: Dr Robert Huddart Cancer Clinic London
Prostate cancer update: 2013 Dr Robert Huddart Cancer Clinic London Recent developments Improved imaging New radiotherapy technologies Radiotherapy for advanced disease Intermittent hormone therapy New
More informationQuando e qual o momento de iniciar os Bifosfonatos no Câncer de Próstata
Quando e qual o momento de iniciar os Bifosfonatos no Câncer de Próstata Igor A. Protzner Morbeck, MD, MSc Professor de Medicina Universidade Católica de Brasília Oncologista Clínico Onco-Vida Brasília-DF
More informationDENOSUMAB. . Peter Harper Guy s, King s & St Thomas & Leaders in Oncology Care (LOC) DENOSUMAB. RANK-L/Bisphosphonates; Bone secondaries & Lung Cancer
DENOSUMAB. Peter Harper Guy s, King s & St Thomas & Leaders in Oncology Care (LOC) DENOSUMAB RANK-L/Bisphosphonates; Bone secondaries & Lung Cancer. Peter Harper Guy s, King s & St Thomas & Leaders in
More informationEfficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with Advanced Cancer
Review Articles Jpn J Clin Oncol 2012;42(8)663 669 doi:10.1093/jjco/hys088 Advance Access Publication 13 June 2012 Efficacy and Safety of Denosumab for the Treatment of Bone Metastases in Patients with
More informationManaging Skeletal Metastases
Managing Skeletal Metastases Alison Stopeck, M.D. Professor of Medicine Director, Breast Cancer Program University of Arizona Cancer Center Tucson, AZ Disclosures: Consulting, research funding, and honoraria
More informationpacientes con metástasis óseas Dr. JOSÉ MANUEL MARTÍNEZ SESMERO Hospital Virgen de la Salud de Toledo Toledo
De la evidencia al beneficio de los pacientes con metástasis óseas Dr. JOSÉ MANUEL MARTÍNEZ SESMERO Hospital Virgen de la Salud de Toledo Toledo ÍNDICE 1. Eventos relacionados con el esqueleto (EREs).
More informationBREAST CANCER AND BONE HEALTH
BREAST CANCER AND BONE HEALTH Rowena Ridout, MD, FRCPC Toronto Western Hospital Osteoporosis Program University Health Network / Mount Sinai Hospital rowena.ridout@uhn.ca None to declare Conflicts of Interest
More informationPalliative treatments for lung cancer: What can the oncologist do?
Palliative treatments for lung cancer: What can the oncologist do? Neil Bayman Consultant Clinical Oncologist GM Cancer Palliative Care and Lung Cancer Education Event Manchester, 31 st January 2017 Most
More informationRadiotherapy symptoms control in bone mets. Francesco Cellini GemelliART. Ernesto Maranzano,MD. Session 5: Symptoms management
Session 5: Symptoms management Radiotherapy symptoms control in bone mets Francesco Cellini GemelliART Ernesto Maranzano,MD Director of Oncology Department Chief of Radiation Oncology Centre S. Maria Hospital
More informationBisphosphonates in the Management of. Myeloma Bone Disease
Bisphosphonates in the Management of Myeloma Bone Disease James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Myeloma Bone Disease Myeloma cells
More informationProduct: Denosumab (AMG 162) Abbreviated Clinical Study Report: (Extension Phase Results) Date: 24 August 2010 Page Page 2 of 2 of
Product: Denosumab (MG 162) bbreviated Clinical Study Report: 20040114 (Extension Phase Results) Date: 24 ugust 2010 Page Page 2 of 2 of 1314 55 2. SYNOPSIS Name of Sponsor: mgen Inc. Name of Finished
More informationBisphosphonates and RANK-L inhibitors in Myeloma
Bisphosphonates and RANK-L inhibitors in Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of Medicine Mayo
More informationSYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223
SYSTEMIC THERAPIES FOR CRPC: Chemotherapy and Radium-223 ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 4-5 October 2018 Disclosures Participation in advisory boards:
More informationAlpha-emitting Radionuclides: Ra-223
Alpha-emitting Radionuclides: Ra-223 prof. dr. K. Goffin Nuclear Medicine and Molecular Imaging Department of Imaging & Pathology UZ Leuven KU Leuven Belgium International Course on Theranostics and Molecular
More informationAdvanced Prostate Cancer. SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin
Advanced Prostate Cancer SAMO Masterclass 17 th of March 2017 PD Dr. med. Aurelius Omlin aurelius.omlin@kssg.ch Conflicts of Interest Research Support: TEVA, Janssen Advisory Rolle: Astra Zeneca, Astellas,
More informationChallenges in the management of metastatic prostate cancer
Oncology 323 Challenges in the management of metastatic prostate cancer A significant number of men with prostate cancer will be elderly. Although some of the issues they face will be the same as their
More informationPREVENTING BROKEN BONES:
PREVENTING BROKEN BONES: Your guide to understanding how XGEVA can help prevent broken bones and other serious bone problems* when cancer from solid tumors spreads to your bones.1 *Serious bone problems
More informationIncorporating New Agents into the Treatment Paradigm for Prostate Cancer
Incorporating New Agents into the Treatment Paradigm for Prostate Cancer Dr. Celestia S. Higano FACP, Professor, Medicine and Urology, Uni. of Washington Member, Fred Hutchinson Cancer Research Center
More informationbone HEALTH IN FOCUS UNDERSTANDING THE IMPORTANCE OF BONE HEALTH WHEN LIVING WITH METASTATIC BREAST CANCER
bone HEALTH IN FOCUS UNDERSTANDING THE IMPORTANCE OF BONE HEALTH WHEN LIVING WITH METASTATIC BREAST CANCER IF YOU VE BEEN DIAGNOSED WITH METASTATIC BREAST CANCER (ALSO KNOWN AS STAGE IV BREAST CANCER),
More informationWinston Tan MD FACP Associate Professor of Medicine Mayo Clinic Florida
Winston Tan MD FACP Associate Professor of Medicine Mayo Clinic Florida } none } To develop an understanding of the management of bone metastasis through a multidisciplinary approach } Enable the learner
More informationBone Health in the Cancer Patient
Bone Health in the Cancer Patient Stavroula Otis, M.D. Primary Care and Oncology: Practical Lessons Conference Brea Community Center May 10, 2018 Sacred Encounters Perfect Care Healthiest Communities Why
More informationIndex Patients 3& 4. Guideline Statements 10/11/2014. Enzalutamide Reduced the Risk of Death
//4 Prolonged Radiographic Progression-Free Survival Reduced the Risk of Death Overall ITT Population Estimated median rpfs, months (9% CI): : NYR (.8 NYR); placebo:.9 (.7.4) rpfs (%) ( Enza 9 8 7 4 8
More informationRadiopharmaceuticals for treating CRPC patients with metastatic bone disease 2014/6/27
Radiopharmaceuticals for treating CRPC patients with metastatic bone disease 和信醫院黃玉儀 2014/6/27 Bone metastases in prostate cancer The most common site of metastasis in prostate cancer In >90% patients
More informationSaad et al [12] Metastatic CRPC. Bhoopalam et al [14] M0 PCa on ADT <1 yr vs >1 yr ADT
Evolution of Treatment Options for Patients with and Bone Metastases Trials of Treatments for Castration-Resistant Prostrate Cancer Mentioned in This Review Bisphosphonates (Zometa) 4 mg IV 8 mg IV ( to
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationBone Metastases and Osteoporosis
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Bone Metastases and Osteoporosis Bone Metastases Version 2002: Dall / Fersis / Friedrich Version 2003 2009: Bischoff / Böhme
More informationBone metastases of solid tumors Diagnosis and management by
Bone metastases of solid tumors Diagnosis and management by Dr/RASHA M Abd el Motagaly oncology consultant Nasser institute adult oncology unit 3/27/2010 1 Goals 1- Know the multitude of problem of bone
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Rhona McMenemin Consultant in Clinical Oncology The
More informationBone health in cancer patients: ESMO Clinical Practice Guidelines
clinical practice guidelines Annals of Oncology 25 (Supplement 3): iii124 iii137, 2014 doi:10.1093/annonc/mdu103 Published online 29 April 2014 clinical practice guidelines Bone health in cancer patients:
More informationMETASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 /
METASTATIC PROSTATE CANCER MANAGEMENT K I R U B E L T E F E R A M. D. T R I H E A LT H C A N C E R I N S T I T U T E 0 1 / 3 1 / 2 0 1 8 Prostate Cancer- Statistics Most common cancer in men after a skin
More informationManagement of metastatic bone disease
Oncology 33 Management of metastatic bone disease Metastatic bone disease is a common cause of pain and disability for patients with advanced cancer. Early detection and appropriate management can limit
More informationΛουκάς Κοντοβίνης, παθολόγος - ογκολόγος.
Λουκάς Κοντοβίνης, παθολόγος - ογκολόγος l.kontovinis@oncomedicare.com Nuclear Medicine Review 2011, 14, 2: 96 104 N Engl J Med 2004;350:1655-64 Nuclear Medicine Review 2011, 14, 2: 96 104 N Engl J Med
More informationManagement of Bone Metastasis in Breast Cancer: Drugs, Dosing and Duration
Management of Bone Metastasis in Breast Cancer: Drugs, Dosing and Duration Kara Laing, MD, FRCPC Chair and Associate Professor, Discipline of Oncology Memorial University of Newfoundland Medical Oncologist,
More informationMetastatic Disease of the Proximal Femur
CASE REPORT Metastatic Disease of the Proximal Femur WI Faisham, M.Med{Ortho)*, W Zulmi, M.S{Ortho)*, B M Biswal, MBBS** 'Department of Orthopaedic, "Department of Oncology and Radiotherapy, School of
More informationPLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE. Daan De Maeseneer, Medisch Oncoloog
PLAATS VAN DE CHEMOTHERAPIE IN DE BEHANDELING VAN EEN PROSTAATCARCINOOM: EEN UPDATE Daan De Maeseneer, Medisch Oncoloog 1 Overview DEAT PSA/Tumor Burden METASTASES INITIAL DIAGNOSIS & THERAPY ADT CRP SREs/
More informationQuestions and Answers About Breast Cancer, Bone Metastases, & Treatment-Related Bone Loss. A Publication of The Bone and Cancer Foundation
Questions and Answers About Breast Cancer, Bone Metastases, & Treatment-Related Bone Loss A Publication of The Bone and Cancer Foundation Contents This publication includes important information about
More informationAdvanced Prostate Cancer
Advanced Prostate Cancer SAMO Masterclass 4 th March 2016 Aurelius Omlin Conflicts of interest Advisory Rolle: Astra Zeneca, Astellas, Bayer, Janssen, Pfizer, Sanofi Aventis Research support: TEVA, Janssen
More informationAdvanced Prostate Cancer. November Jose W. Avitia, M.D
Advanced Prostate Cancer November 4 2017 Jose W. Avitia, M.D In 2017 161,000 new cases of prostate cancer diagnosed in US, mostly with elevated PSA 5-10% will present with metastatic disease In 2017: 26,000
More informationPlease consider the following information on ZYTIGA (abiraterone acetate). ZYTIGA - Compendia Communication - NCCN LATITUDE and STAMPEDE June 2017
Page 1 of 2 Janssen Scientific Affairs, LLC 1125 Trenton-Harbourton Road PO Box 200 Titusville, NJ 08560 800.526.7736 tel 609.730.3138 fax June 08, 2017 Joan McClure 275 Commerce Drive #300 Fort Washington,
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationSESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia
SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract on Prostate Cancer) In Oncologia Divisione di Oncologia Medica Unità Tumori Genitourinari SESSIONE PLATINUM SERIES (Best Papers Poster o Abstract
More informationBreast Cancer and Bone Health. Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield
Breast Cancer and Bone Health Robert Coleman, Cancer Research Centre, Weston Park Hospital, Sheffield Breast Cancer and Bone Health Normal Bone Health Impact of Cancer Therapies on Bone Health Therapeutic
More informationSession 5: Isotope therapies and palliative radiotherapy
Session 5: Isotope therapies and palliative radiotherapy Jeffrey Tuan, FRCR Radiation Oncology National Cancer Centre Singapore 15 Dec 2016 Bone metastases SREs are clinically important endpoints The burden
More informationQuestions and Answers About Breast Cancer, Bone Metastases, & Treatment-Related Bone Loss. A Publication of The Bone and Cancer Foundation
Questions and Answers About Breast Cancer, Bone Metastases, & Treatment-Related Bone Loss A Publication of The Bone and Cancer Foundation Contents This publication includes important information about
More informationEfficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data
Efficacy of Ibandronate in Metastatic Bone Disease: Review of Clinical Data Richard Bell The Andrew Love Cancer Centre Cancer Services, Medical Oncology, Geelong, Victoria, Australia Key Words. Bisphosphonate
More informationInitial Hormone Therapy
Initial Hormone Therapy Alan Horwich Institute of Cancer Research and Royal Marsden Hospital, London, UK Alan.Horwich@icr.ac.uk MANAGEMENT OF PROSTATE CANCER Treatment windows Subclinical Localised PSA
More informationBone Metastases. Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. AGO e. V. in der DGGG e.v. sowie in der DKG e.v.
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Bone Metastases Bone Metastases Version 2002: Dall / Fersis / Friedrich Versions 2003 2011: Bischoff / Böhme / Brunnert / Diel
More informationHybrid bone scintigraphy in gastrointestinal malignancies Institutional Experience
Hybrid bone scintigraphy in gastrointestinal malignancies Institutional Experience Nazia Rashid 1, Saima Riaz 1, Humayun Bashir 1, Shafqat Mehmood 2 1 Nuclear Medicine Department ad 2 Internal Medicine
More informationBone metastases in hematology
Botziekte bij hematologische tumoren Prof. Dr. Michel Delforge Hematologie, UZ Leuven Bone metastases in hematology The bone marrow is the source of many hematological malignancies However, bone damage
More informationZoledronic Acid Is Superior to Pamidronate for the Treatment of Bone Metastases in Breast Carcinoma Patients with at Least One Osteolytic Lesion
36 Zoledronic Acid Is Superior to Pamidronate for the Treatment of Bone Metastases in Breast Carcinoma Patients with at Least One Osteolytic Lesion Lee S. Rosen, M.D. 1 David H. Gordon, M.D. 2 William
More informationGUIDELINES ON THE USE OF BISPHOSPHONATES IN PALLIATIVE CARE. November 2007(Amended July 2008)
Yorkshire Palliative Medicine Clinical Guidelines Group GUIDELINES ON THE USE OF BISPHOSPHONATES IN PALLIATIVE CARE November 2007(Amended July 2008) Authors: Dr Kath Lambert and Dr Liz Brown, on behalf
More informationEvaluation of prognostic scoring systems for bone metastases using single center data
MOLECULAR AND CLINICAL ONCOLOGY 3: 1361-1370, 2015 Evaluation of prognostic scoring systems for bone metastases using single center data HIROFUMI SHIMADA 1, TAKAO SETOGUCHI 2, SHUNSUKE NAKAMURA 1, MASAHIRO
More informationApproved SYNOPSIS. Product: Denosumab (AMG 162) Interim Synopsis Clinical Study Report: Date: 23 July 2010.
Page 2 of 24012 SYNOPSIS Name of Sponsor: Amgen Inc Name of Finished Product: not applicable Name of Active Ingredient: denosumab (AMG 162) Title of Study: A Randomized, Double-Blind, Multicenter Study
More informationRADIONUCLIDE THERAPY FOR PALLIATION OF PAIN FROM BONY METASTASES
RADIONUCLIDE THERAPY FOR PALLIATION OF PAIN FROM BONY METASTASES Overview and Topics to Be Covered Reviews the use of radionuclide therapy in nuclear medicine for palliation of pain due to bony metastases.
More informationRipamonti C, et al. ASCO 2012 (Abstract 9005)
ZOOM: A Prospective, Randomized Trial of Zoledronic Acid for Long-term Treatment in Patients With Bone-Metastatic Breast Cancer After 1 Year of Standard Zoledronic Acid Treatment D. Amadori, M. Aglietta,
More informationNovel treatment for castration-resistant prostate cancer
Novel treatment for castration-resistant prostate cancer Cora N. Sternberg, MD, FACP Chair, Department of Medical Oncology San Camillo and Forlanini Hospitals Rome, Italy Treatment options for patients
More informationScottish Medicines Consortium
Scottish Medicines Consortium zoledronic acid 5mg/100ml solution for infusion (Aclasta) No. (317/06) Novartis 8 September 2006 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationRecognition & Treatment of Malignant Spinal Cord Compression Study Day
Recognition & Treatment of Malignant Spinal Cord Compression Study Day 11 th May 2017 Dr Bernie Foran Consultant Clinical Oncologist & Honorary Senior Lecturer Weston Park Hospital Outline of Talk Clinical
More informationFrom Fragile to Firm. Monika Starosta MD. Advocate Medical Group
From Fragile to Firm Monika Starosta MD Advocate Medical Group Bone Remodeling 10% remodeled each year Calcium homoeostasis Maintain Mechanical strength Replace Osteocytes Release Growth Factors Bone remodeling
More informationAnalysis of Denosumab on Skeletal-Related Events in Patients With Advanced Breast Cancer
Downloaded on 12 07 2018. Single-user license only. Copyright 2018 by the Oncology Nursing Society. For permission to post online, reprint, adapt, or reuse, please email pubpermissions@ons.org Online Exclusive
More informationOUR EXPERIENCE WITH ZOLEDRONIC ACID IN THE TREATMENT OF PATIENTS WITH NON- SMALL CELL LUNG CANCER AND BONE METASTASES
ISSN: 1312-773X (Online) DOI: 10.5272/jimab.2013191.391 Journal of IMAB - Annual Proceeding (Scientific Papers) 2013, vol. 19, issue 1 OUR EXPERIENCE WITH ZOLEDRONIC ACID IN THE TREATMENT OF PATIENTS WITH
More informationThe Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD
Februray, 2013 The Return of My Cancer -Emerging Effective Therapies Jianqing Lin, MD Why/How my cancer is back after surgery and/or radiation? Undetected micro-metastatic disease (spreading) before local
More informationFREQUENTLY ASKED QUESTIONS
FREQUENTLY ASKED QUESTIONS The following questions are representative of questions that patients and family members ask when they visit the Bone and Cancer Foundation website or contact the Foundation
More informationBone resorption predicts for skeletal complications in metastatic bone disease
British Journal of Cancer (2003) 89, 2031 2037 All rights reserved 0007 0920/03 $25.00 www.bjcancer.com Bone resorption predicts for skeletal complications in metastatic bone disease JE Brown 1, CS Thomson
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationWhat Lung Cancer Patients Need to Know About Bone Health. A Publication of The Bone and Cancer Foundation
What Lung Cancer Patients Need to Know About Bone Health A Publication of The Bone and Cancer Foundation Contents THIS PUBLICATION PROVIDES IMPORTANT INFORMATION ABOUT THE RELATIONSHIP BETWEEN LUNG CANCER
More informationFarmaci bone-targeted: basi biologiche e razionale d uso. Giovanni Pavanato Rovigo
Farmaci bone-targeted: basi biologiche e razionale d uso Giovanni Pavanato Rovigo DICHIARAZIONE Relatore: Giovanni Pavanato Come da nuova regolamentazione della Commissione Nazionale per la Formazione
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationCoRIPS Research Award 089. Beverley Atherton
CoRIPS Research Award 089 Beverley Atherton Can the early signs and symptoms suggestive of spinal cord compression be identified by radiographers during bone scans by gathering clinical information about
More informationAdjuvant bisphosphonates: our recommendations
Adjuvant bisphosphonates: our recommendations Andreas Makris Mount Vernon Cancer Centre OPTIMA launch meeting, 27 April 2017 Breast Cancer Metastasis Tumour cell colonisation of bone Tumour cell proliferation
More informationIdentification of the Risk Factors of Bone Metastatic among Breast Cancer Women in Al-Bashir Hospital
Advances in Breast Cancer Research, 2018, 7, 120-129 http://www.scirp.org/journal/abcr ISSN Online: 2168-1597 ISSN Print: 2168-1589 Identification of the Risk Factors of Bone Metastatic among Breast Cancer
More information